Denosumab and giant cell tumour of bone-a review and future management considerations

Current Oncology

Volumn 20, Issue 5, 2013, Pages

  Xu, S F ^a   Adams, B ^b   Yu, Xiu Chun ^a   Xu, M ^a  

^a General Hospital of Ji'nan Military Region   (China)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Bone turnover; Denosumab; Giant cell tumour of bone; RANKL; Receptor activator of nuclear factor B ligand

Indexed keywords

ALENDRONIC ACID; AMGN 0007; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BINDING AFFINITY; BONE CANCER; BONE DESTRUCTION; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURGERY; CATARACT; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FEVER; GIANT CELL; HUMAN; HYPERHIDROSIS; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; LIMB PAIN; LOADING DRUG DOSE; LUNG METASTASIS; LUNG RESECTION; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MYALGIA; NONHUMAN; OSTEOCLAST; OSTEOCLASTOMA; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; RISK BENEFIT ANALYSIS; SCIATICA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WIDE EXCISION;

EID: 84886939143     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1497     Document Type: Article

References (48)

1. Derbel O, Zrounba P, Chassagne-Clément C, et al. An unusual giant cell tumor of the thyroid: case report and review of the literature. J Clin Endocrinol Metab 2013;98:1-6.
2. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Surg 2013;21:118-26.
3. Huang L, Xu J, Wood DJ, Zheng MH. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of nf-κB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 2000;156:761-7.
4. Balke M, Hardes J. Denosumab: a breakthrough in treatment of giant-cell tumour of bone? Lancet Oncol 2010;11:218-19.
5. Szendroi M. Giant-cell tumour of bone. J Bone Joint Surg Br 2004;86:5-12.
6. Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors 2009;1:e52.
7. United Kingdom, National Institute for Health Research (nihr), Horizon Scanning Centre. Denosumab (Xgeva) for Recurrent or Unresectable Giant Cell Tumour of the Bone-First or Second Line. Birmingham, U.K.: nihr; 2012.
8. Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics 2013;33:197-211.
9. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011;469:591-9.
10. Miller G, Bettelli G, Fabbri N, Capanna R. Curettage of giant cell tumor of bone. Introduction-material and methods. Chir Organi Mov 1990;75(suppl 1):203.
11. Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999;81:811-20.
12. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 2011;469:1181-7.
13. Siebenrock KA, Unni KK, Rock MG. Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br 1998;80:43-7.
14. Ruka W, Rutkowski P, Morysiński T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys 2010;78:494-8.
15. Mittal S, Goswami C, Kanoria N, Bhattacharya A. Post-irradiation angiosarcoma of bone. J Cancer Res Ther 2007;3:96-9.
16. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, Griffith JF. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008;42:68-73.
17. Kaban LB, Troulis MJ, Ebb D, August M, Hornicek FJ, Dodson TB. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002;60:1103-11.
18. Yasko AW. Interferon therapy for vascular tumors of bone. Curr Opin Orthop 2001;12:514-18.
19. Coleman RE, McCloskey EV. Bisphosphonates in oncology. Bone 2011;49:71-6.
20. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
21. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
22. Body JJ, Greipp P, Coleman RE, et al. A phase i study of amgn-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(suppl):887-92.
23. Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (opg) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival? Breast Cancer Res Treat 2005;92:207-15.
24. Kitazawa S, Kitazawa R. rank ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002;198:228-36.
25. Akiyama T, Choong PF, Dass CR. rank-Fc inhibits malignancy via inhibiting Erk activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 2010;27:207-15.
26. Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong PF. Systemic rank-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J Pharm Pharmacol 2010;62:470-6.
27. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-8.
28. Fizazi K, Lipton A, Mariette X, et al. Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71.
29. Lipton A, Steger GG, Figueroa J, et al. Randomized activecontrolled phase ii study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7.
30. Dougall WC, Chaisson M. The rank/rankl/opg triad in cancerinduced bone diseases. Cancer Metastasis Rev 2006;25:541-9.
31. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of amg 162, a fully human monoclonal antibody to rankl, in postmenopausal women. J Bone Miner Res 2004;19:1059-66.
32. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-82.
33. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.
34. Smith MR, Saad F, Coleman R, et al. Denosumab and bonemetastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebocontrolled trial. Lancet 2012;379:39-46.
35. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J Clin Oncol 2010;28:5132-9.
36. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study. Lancet 2011;377:813-22.
37. Henry DH, Costa L, Goldwasser F, et al. Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
38. Jilani A, Garrett Z, Sutcliffe F, Stevens A. nice guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours. Lancet Oncol 2012;13:1194-5.
39. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80.
40. Blay J, Chawla SP, Martin Broto J, et al. Denosumab safety and efficacy in giant cell tumor of bone (gctb): interim results from a phase ii study [abstract 10034]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstract ID=82649; cited August 16, 2013]
41. Electronic Medicines Compendium (emc). Xgeva: Summary of Product Characteristics [Web page]. Cambridge, U.K.: Amgen; 2012. [Most recent version available at: http://www. medicines.org.uk/emc/medicine/24755/SPC/XGEVA/; cited June 13, 2012]
42. Lipton A, Siena S, Rader M, et al. Comparison of denosumab versus zoledronic acid (za) for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials [abstract 1249P]. Ann Oncol 2010;21(suppl 8):viii380.
43. Silva-Fernández L, Rosario MP, Martínez-López JA, Carmona L, Loza E. Denosumab for the treatment of osteoporosis: a systematic literature review. Reumatol Clin 2013;9:42-52.
44. Ford JA, Jones R, Elders A, et al. Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer 2013;49:416-30.
45. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 2013;39:97-104.
46. Thomas D, Carriere P, Jacobs I. Safety of denosumab in giantcell tumour of bone. Lancet Oncol 2010;11:815.
47. Kyrgidis A, Toulis K. Safety and efficacy of denosumab in giant-cell tumour of bone. Lancet Oncol 2010;11:513-14.
48. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987;69:106-14.